An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
Maternity and Children hospital, Mecca, Saudi Arabia
Health insurance hospital, Banī Suwayf, Egypt
Faculty of medicine, Beni-suef univeristy - Beni-Suef university hospital, Banī Suwayf, Egypt
St. Paul's Hospital, Vancouver, British Columbia, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Royal United Hospital, Bath, United Kingdom
Belfast City Hospital, Belfast, United Kingdom
Southmead Hospital, Bristol, United Kingdom
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Bugando Medical Centre, Mwanza, Tanzania
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Centre de Recherche et de Lutte contre la Drépanocytose de Bamako (CRLD), Bamako, Mali
CHU Pointe-à-Pitre/Abymes, Pointe-à-Pitre, Guadeloupe
CHU d'Angers, Angers, France
Boston Children's Hospital, Boston, Massachusetts, United States
Cleveland Clinic Children's, Cleveland, Ohio, United States
Carle Foundation Hospital, Urbana, Illinois, United States
CHLA, Los Angeles, California, United States
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.